Evaluation and Management of Post-Chemotherapy Peripheral Neuropathy
Diagnostic Approach
- The American Society of Clinical Oncology recommends beginning with targeted laboratory testing to identify treatable causes and rule out contributing factors, including fasting blood glucose, vitamin B12 with methylmalonic acid, thyroid-stimulating hormone, and serum protein electrophoresis with immunofixation 1
- Chemotherapy exposure details, such as taxane, platinum, or vinca alkaloid exposure, should be specifically documented as these are primary causative agents 2
- A temporal relationship between symptoms and chemotherapy exposure should be assessed, with symptoms beginning during or within months after chemotherapy suggesting chemotherapy-induced peripheral neuropathy (CIPN) 1
Management Algorithm
- The American College of Physicians recommends duloxetine 30-60 mg daily as the first-line treatment for CIPN, with evidence demonstrating significant improvement in both pain and numbness 5, 1, 6
- Pregabalin may be considered as a second-line option, although evidence is mixed, and it is FDA-approved for diabetic peripheral neuropathy but not specifically for CIPN 5, 1
- Gabapentin has limited evidence for CIPN specifically, but may provide some benefit in diabetic neuropathy, with target doses of 1200-3600 mg daily 6
Non-Pharmacologic Interventions
- The American Cancer Society recommends a home-based, moderate-intensity walking and resistance exercise program to reduce CIPN symptoms, including numbness and tingling 2, 5
- Fall prevention measures, such as non-slip footwear and handrails, should be implemented to reduce the risk of falls due to vestibulo-spinal dysfunction 4
- Podiatry referral and occupational therapy may be beneficial for foot care and adaptive devices to assist with fine motor tasks 5
Prognosis and Long-Term Management
- Patients should be counseled that 15-40% may have persistent symptoms after taxane chemotherapy, although most improve gradually with time and rehabilitation 5, 4
- Ongoing monitoring with validated tools, such as the EORTC QLQ-CIPN20 or FACT/GOG-Ntx, helps track progression and should be implemented 5